Amylin, Takeda Stop Mid-stage Study of Combination Treatment for Obesity
From Canadian Press DataFile (March 16, 2011)
Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Wednesday they have suspended a mid-stage clinical trial of a combination obesity treatment to investigate a new ``antibody-related laboratory finding" with one of the drugs.
The companies were studying the safety and effectiveness of the combination of the injectable synthetic hormones pramlintide and metreleptin. They said in a statement the laboratory finding in two patients was connected to metreleptin.
An Amylin spokeswoman declined to elaborate on the finding Wednesday morning. She said the study was separate from another mid-stage trial completed by San Diego-based Amylin and Takeda, which is based in Japan. The companies said last month they were planning a late-stage testing of the combination, and that planning will continue.
The companies have said patients who took the combination had sustained weight loss during a 52-week study, while patients who took a placebo lost weight initially but were not able to sustain it.
Amylin shares rose 15 cents, or 1.4 per cent, to $11.18 in morning trading after falling as low as $10.71 earlier in the session.
The company's stock also tumbled earlier this month, when it said the potential diabetes treatment Bydureon proved inferior to Novo Nordisk's Victoza, according to initial results from a late-stage study comparing the drugs. Amylin is developing Bydureon with Indianapolis-based Eli Lilly and Co. and Alkermes Inc. of Waltham, Mass.
They're developing Bydureon as a longer-lasting, once-weekly version of Byetta, which is injected twice a day. Bydureon aims to treat patients with type 2 diabetes.
Posted: March 2011